Institutional members access full text with Ovid®

Share this article on:

Are There Placebo Effects in the Medication Treatment of Children With Attention-Deficit Hyperactivity Disorder?

Waschbusch, Daniel A. PhD*; Pelham, William E. Jr PhD; Waxmonsky, James MD; Johnston, Charlotte PhD§

Journal of Developmental & Behavioral Pediatrics: April 2009 - Volume 30 - Issue 2 - p 158-168
doi: 10.1097/DBP.0b013e31819f1c15
Review Article

Placebos have been shown to produce significant positive changes in several health and mental health problems, referred to as placebo effects. Although it is well established that stimulant medication is an empirically supported treatment for children with attention-deficit hyperactivity disorder (ADHD), little is known about the role of placebos in the medication treatment of children with ADHD. This article reviews existing studies that evaluate whether placebos produce significant changes in children with ADHD. Published literature and the author's own empirical work were used to evaluate whether placebo effects are present in the medication treatment of children with ADHD. There is little evidence that placebos produce significant changes in the behavior or cognition of elementary school-age children with ADHD. However, there may be significant placebo effects in adults who evaluate children with ADHD. Evidence suggests that parents and teachers tend to evaluate children with ADHD more positively when they believe the child has been administered stimulant medication and they tend to attribute positive changes to medication even when medication has not actually been administered. Several viable mechanisms for these placebo effects are suggested.

From the *Departments of Pediatrics, †Pediatric and Psychology, and ‡Department of Psychiatry, University at Buffalo—SUNY, Buffalo, NY; and §Department of Psychology, University of British Columbia, Vancouver, BC.

The first three authors were supported, in part, by Grants from the National Institute of Mental Health (MH53554, MH069614, MH069434, MH078051, MH080791, MH064154), National Institute of Alcohol Abuse and Alcoholism (AA11873), National Institute on Drug Abuse (DA12414), Department of Education—Institute of Educational Sciences (L03000665A, R324B060045, R324J060024), Department of Health and Human Services—Administration for Children and Families (90YR0017/01), and by Eli Lilly Corporation.

Address for reprints: Daniel A. Waschbusch, PhD, Center for Children and Families, Diefendorf Hall Room 106, University at Buffalo—SUNY, 3435 Main Street Building 20, Buffalo, NY 14214; e-mail: dw35@buffalo.edu.

© 2009 Lippincott Williams & Wilkins, Inc.